Inventiva (NASDAQ:IVA) Shares Gap Up – Time to Buy?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) gapped up before the market opened on Monday . The stock had previously closed at $4.00, but opened at $4.16. Inventiva shares last traded at $4.0640, with a volume of 32,409 shares.

Analyst Ratings Changes

IVA has been the topic of a number of research analyst reports. Canaccord Genuity Group restated a “buy” rating and issued a $20.00 price target on shares of Inventiva in a research note on Tuesday, September 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Inventiva to a “hold” rating in a research report on Saturday, October 18th. Piper Sandler began coverage on shares of Inventiva in a report on Wednesday, August 27th. They set an “overweight” rating and a $26.00 price target for the company. Finally, Guggenheim dropped their price target on Inventiva from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.29.

Inventiva Trading Up 3.0%

The stock’s fifty day simple moving average is $5.12 and its two-hundred day simple moving average is $4.20.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Creative Planning acquired a new position in Inventiva during the 2nd quarter worth about $32,000. Wealth Enhancement Advisory Services LLC raised its position in shares of Inventiva by 54.5% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 16,558 shares of the company’s stock worth $50,000 after acquiring an additional 5,843 shares during the last quarter. NewEdge Advisors LLC bought a new position in shares of Inventiva during the third quarter worth about $116,000. Finally, Millennium Management LLC acquired a new position in shares of Inventiva in the third quarter worth approximately $649,000. 19.06% of the stock is owned by institutional investors.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.